A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.
You may also be interested in...
Deal Watch: Allergan, Regeneron Both Look To Hydrogel Tech
Most of the significant deal-making action during the past week took place in Asia as Piramal made a play to increase its injectables business, an Eisai affiliate out-licensed rights to ovarian cancer candidate farletuzumab, and EpimAb and Kymab agreed to collaborate on bispecific antibody therapeutics.
Eisai Will Try For Halaven Label Expansion, Despite Phase III Failure
Even though Eisai’s Halaven showed an unprecedented overall survival effect in a very tough-to-treat breast cancer population, the drug appears to have flopped in a head-to-head study against Xeloda in an earlier line of therapy. Nevertheless, Eisai vows to pursue a regulatory filing that would expand the drug’s label, as planned.
Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte
Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.